M

    Minerva Neurosciences Inc (NERV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.56
    -0.28 (-5.79%)

    Market Cap: $217.73M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    -318.67%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.18
    Range$-0.22 - $-0.14
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.23-25.0%
    60d ago$-0.23-25.0%
    30d ago$-0.23-25.0%
    7d ago$-0.23-25.0%
    Current$-0.18
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.25
    Range$-0.25 - $-0.25
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.25---
    Sep 26EST
    		-$-0.18---
    Jun 26
    Reported Aug 4
    		$-0.46$-0.01-4500.00%Miss-7.0%
    Mar 26
    Reported May 5
    		$-0.17$-0.14-23.19%Miss+66.0%
    Dec 25
    Reported Mar 11
    		$-25.51$-0.30-8403.33%Miss-4455.4%
    Sep 25
    Reported Nov 5
    		$-0.36$-0.35-2.86%Miss-112.1%
    Jun 25
    Reported Aug 14
    		$-0.43N/A+52.22%Beat+60.6%
    Mar 25
    Reported May 13
    		$-0.50N/A+53.27%Beat+55.8%
    Dec 24
    Reported Feb 25
    		$-0.56$-1.05+46.67%Beat+59.7%
    Sep 24
    Reported Nov 5
    		$2.97$-1.01+394.06%Beat+388.3%
    Jun 24
    Reported Aug 6
    		$-1.09$-0.97-12.37%Miss+2.7%
    Mar 24
    Reported May 1
    		$-1.13$-1.20+5.83%Beat+13.7%
    Dec 23
    Reported Feb 22
    		$-1.39$-0.88-57.95%Miss-10.3%
    Sep 23
    Reported Nov 7
    		$-1.03$-0.77-33.77%Miss+20.2%
    Jun 23
    Reported Aug 1
    		$-1.12$-0.44-154.55%Miss+31.3%
    Mar 23
    Reported May 15
    		$-1.31$-1.63+19.63%Beat+28.8%
    Dec 22
    Reported Mar 8
    		$-1.26$-0.92-36.96%Miss+68.5%
    Sep 22
    Reported Nov 9
    		$-1.29$-1.41+8.51%Beat+26.7%
    Jun 22
    Reported Aug 9
    		$-1.63$-1.68+2.98%Beat+18.5%
    Mar 22
    Reported May 4
    		$-1.84$-1.52-21.05%Miss-9.5%
    Dec 21
    Reported Mar 1
    		$-4.00$-1.50-166.67%Miss-177.8%
    Sep 21
    Reported Nov 8
    		$-1.76$-1.76+0.00%Beat-15.8%
    Jun 21
    Reported Aug 2
    		$-2.00$-1.39-43.88%Miss-134.2%
    Mar 21
    Reported May 12
    		$-1.68$1.71-198.25%Miss+32.3%
    Dec 20
    Reported Mar 8
    		$-1.44$-1.53+5.88%Beat+76.6%
    Sep 20
    Reported Nov 2
    		$-1.52$-1.83+16.94%Beat+47.2%
    Jun 20
    Reported Aug 3
    		$5.84$-2.32+351.72%Beat+328.1%
    Mar 20
    Reported May 4
    		$-2.48$-2.86+13.29%Beat+24.4%
    Dec 19
    Reported Mar 9
    		$-6.16$-3.04-102.63%Miss-126.5%
    Sep 19
    Reported Nov 4
    		$-2.88$-3.01+4.32%Beat-16.1%
    Jun 19
    Reported Aug 5
    		$-2.56$-3.33+23.12%Beat+0.0%
    Mar 19
    Reported May 6
    		$-3.28$-2.85-15.09%Miss-28.1%
    Dec 18
    Reported Mar 12
    		$-2.72$-2.84+4.23%Beat-41.7%
    Sep 18
    Reported Nov 5
    		$-2.48$-3.08+19.48%Beat-10.7%
    Jun 18
    Reported Aug 2
    		$-2.56$-3.15+18.73%Beat-18.5%
    Mar 18
    Reported May 3
    		$-2.56$-2.07-23.67%Miss-6.7%
    Dec 17
    Reported Mar 12
    		$-1.92$-3.04+36.84%Beat+14.3%
    Sep 17
    Reported Nov 6
    		$-2.24$-2.08-7.69%Miss-16.7%
    Jun 17
    Reported Aug 3
    		$-2.16$-2.56+15.63%Beat-
    Mar 17
    Reported May 4
    		$-2.40$-2.24-7.14%Miss-
    Dec 16
    Reported Mar 13
    		$-2.24$-2.00-12.00%Miss-
    Sep 16
    Reported Nov 3
    		$-1.92$-1.64-17.07%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.17EV/EBITDA2.60x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-675.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage1.04x
    Current Ratio20.14xQuick Ratio20.14x
    Trading Statistics
    Beta-0.11Avg Volume247.59K
    52-Week High$8.8052-Week Low$1.93

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.87
    SMA 20$4.58
    SMA 50$4.52
    SMA 200$5.07
    EMA 10$4.81
    EMA 20$4.67
    EMA 50$4.65
    EMA 200$4.64

    MACD

    Line: 0.15Signal: 0.11Hist: 0.04

    ADX

    ADX: 24.8+DI: 27.0-DI: 18.5

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down52.0
    PSAR$5.63

    Bollinger Bands

    Upper Band$5.36
    Lower Band$3.80
    %B Position3415%(Upper)
    Band Width0.49

    RSI (14-Day)

    Neutral
    48.8

    Momentum Oscillators

    Stoch %K56.1
    Stoch %D70.2
    Williams %R-59.8
    ROC (10d)3.2%
    Momentum0.14
    CCI (20d)12.8
    MFI (14d)78.2

    Volatility Measures

    ATR (14d)$0.40(8.7%)
    StdDev (20d)0.39
    Hist Vol101.8%(High)

    Volume Flow

    VWAP$4.66
    OBV178.0M
    AD Line-142.1M
    CMF (20d)-0.008

    Volume Metrics

    Avg Vol (20d)255.8K
    Vol Ratio0.5x(Low)
    VWMA (20d)$4.70

    Pivot Points

    R3$5.63
    R2$5.47
    R1$5.15
    Pivot Point$4.99
    S1$4.67
    S2$4.51
    S3$4.19

    Advanced Oscillators

    TSI10.91
    Ultimate Osc40.6
    KST98.89

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$42,218$0$0$0$0$0
    Cost of Revenue$0$0$1,360$0$0$0$21,109$0$0$0$7,746$0
    Gross Profit$0$0$-1,360$0$0$0$21,109$0$0$0$-7,746$0
    Operating Expenses$10.64M$16.67M$4.98M$2.84M$3.37M$3.90M$4.52M$4.37M$6.28M$6.68M$7.17M$6.08M
    R&D$7.19M$5.25M$2.17M$925,377$1.30M$1.36M$1.98M$1.89M$3.86M$4.17M$4.72M$3.44M
    SG&A$3.45M$11.42M$2.81M$1.92M$2.08M$2.54M$2.54M$2.48M$2.42M$2.51M$2.45M$2.64M
    Operating Income$-10,642,159$-16,671,552$-4,981,589$-2,844,348$-3,374,149$-3,902,884$-4,522,155$-4,366,700$-6,277,568$-6,681,963$-7,171,943$-6,079,120
    Interest Income$569,591$629,602$546,523$106,640$136,671$158,288$239,724$313,967$360,755$357,908$358,883$348,681
    Interest Expense$0$0$278.67M$0$0$0$0$0$2.31M$2.25M$2.19M$2.08M
    Income Before Tax$17.48M$-125,402,580$-283,646,840$-2,737,708$-3,237,478$-3,744,596$-4,283,230$22.53M$-8,233,487$-8,568,805$20.97M$-7,815,350
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$17.47M$-125,404,384$-283,667,663$-2,743,954$-3,258,588$-3,752,972$-4,272,048$22.51M$-8,233,487$-8,568,805$-9,022,459$-7,820,446
    EBITDA$16.51M$-126,168,923$-4,980,229$-2,842,987$-3,372,789$-3,901,523$-4,521,594$22.22M$-6,274,516$-6,668,725$-7,164,197$-6,071,375
    EBIT$16.91M$-126,032,182$-4,981,589$-2,844,348$-3,374,149$-3,902,884$-4,522,954$22.21M$-6,282,262$-6,676,470$-7,171,943$-6,079,120
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NERV

    News

    Minerva Neurosciences (NASDAQ: NERV) COO holds 20,872 shares, 750K and 680K options

    Minerva Neurosciences' (NASDAQ: NERV) Chief Operating Officer, Joseph H. Reilly, directly owns 20,872 shares of common stock. Additionally, he holds employee stock options for 1,593,725 shares with varying exercise prices and expiration dates, including significant positions of 750,000 shares and 680,000 shares. The report details the vesting schedules for these options, with some already fully vested and others vesting quarterly over several years.

    Stock Titan•8/20/26•
    Neutral

    Jefferies Upgrades Minerva Neurosciences(NERV.US) to Buy Rating, Raises Target Price to $10

    Jefferies has upgraded Minerva Neurosciences (NERV.US) from a Hold rating to a Buy rating. The firm also increased its price target for Minerva Neurosciences to $10, signaling a strong positive outlook for the company's stock.

    Moomoo•8/14/26•
    Bullish

    Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research

    Zacks Research has downgraded Minerva Neurosciences (NASDAQ:NERV) to a "strong sell" rating, citing weak earnings forecasts despite the company beating Q2 analyst expectations. The biopharmaceutical company's shares opened at $3.92, significantly below its 52-week high, and institutional investors hold a 34.56% stake. Analysts project continued losses for NERV in 2026 and 2027, with some positive long-term EPS forecasts for 2029 and 2030.

    MarketBeat•8/14/26•
    Bearish

    Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants

    Balyasny Asset Management L.P. and its affiliates have reported a beneficial ownership of 9.99% in Minerva Neurosciences, Inc. (NERV). This stake comprises 4,654,212 shares, including 4,257,000 shares held directly by Atlas Private Holdings (Cayman) Ltd. and 397,212 shares exercisable from 13,500 warrants. The warrants are subject to a beneficial ownership limitation, preventing exercises that would exceed the 9.99% threshold.

    Stock Titan•8/14/26•
    Neutral

    Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages

    Minerva Neurosciences, Inc (NASDAQ:NERV) has received a "Reduce" consensus rating from brokerages, with an average 12-month price target of $10.50. This comes as near-term earnings expectations have significantly deteriorated, with HC Wainwright cutting its fiscal 2026 and 2027 EPS estimates, although it projects profitability by 2029. Despite these lowered forecasts, Minerva Neurosciences recently beat analyst estimates for its quarterly loss, reporting -$0.14 EPS against an expected -$0.19.

    MarketBeat•8/14/26•
    Somewhat-Bearish

    Frequently Asked Questions About NERV

    Does NERV pay dividends?
    Minerva Neurosciences Inc (NERV) does not currently pay a regular dividend.
    What is NERV's market cap?
    Minerva Neurosciences Inc (NERV) has a market capitalization of $217.73M with a current stock price of $4.56.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In